EYPT - CIK 0001314102
The table below shows EyePoint Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$240.11M | -$126.23M | $1.88M | -$65.00M | -$50.10M | -$14.44M |
| Capital expenditure | $3.28M | $4.05M | $3.48M | $2.15M | $156.00K | $362.00K |
| Investing cash flow | $68.58M | -$219.35M | -$3.31M | -$17.27M | -$33.12M | -$362.00K |
| Dividends paid | - | - | - | - | - |
EyePoint Pharmaceuticals, Inc. reported operating cash flow of -$240.11M for fiscal year 2025. That is down 90.2% from -$126.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$16.32M (FY 2016) to -$240.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $173.65M | $164.02M | $187.07M | -$690.00K | $216.90M | $37.49M |